SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 102.58 |
| Enterprise Value ($M) | 235.94 |
| Book Value ($M) | 128.81 |
| Book Value / Share | 6.08 |
| Price / Book | 0.80 |
| NCAV ($M) | 52.01 |
| NCAV / Share | 2.45 |
| Price / NCAV | 1.97 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.33 |
| Return on Assets (ROA) | -0.27 |
| Return on Equity (ROE) | -0.60 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 5.21 |
| Current Ratio | 5.21 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 299.85 |
| Assets | 376.65 |
| Liabilities | 247.84 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 67.64 |
| Operating Income | -121.69 |
| Net Income | -116.05 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -78.76 |
| Cash from Investing | 58.23 |
| Cash from Financing | -27.63 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Armistice Capital, Llc | 4.72 | -51.55 | |
| 13G/A | Millennium Management Llc | 3.50 | -44.39 | |
| 13G/A | Vanguard Group Inc | 8.52 | 17.84 | |
| 13G/A | Farallon Capital Partners, L.P. | 9.60 | 30.65 | |
| 13G/A | BlackRock, Inc. | 9.20 | -2.19 | |
| 13G/A | State Street Corp | 2.02 | -71.85 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 85,782 | 624,773 | 13.73 | |
| 123,640 | 582,119 | 21.24 | |
| 228,448 | 805,242 | 28.37 | |
| 218,931 | 814,114 | 26.89 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| EDIT – Editas Medicine, Inc. | ELEV – Elevation Oncology, Inc. |
| ELVN – Enliven Therapeutics, Inc. | ERAS – Erasca, Inc. |
| EWTX – Edgewise Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io